Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

Dopaminergic agents claimed by Sandoz

Sep. 13, 1996

A major breakthrough in the treatment of schizophrenia

Sep. 13, 1996

New compounds from Roche with affinity for benzodiazepine receptors

Sep. 13, 1996

Merck & Co. synthesizes dopamine D4 receptor ligands

Sep. 13, 1996

Divestment of antimigraine treatment from Glaxo Wellcome to Zeneca

Sep. 13, 1996

Controlled-release oral analgesic formulation claimed by Euroceltique

Sep. 13, 1996

Chiron describes a new opiate receptor ligand

Sep. 13, 1996

Delta-opioid agonists for pain

Sep. 13, 1996

NK1 antagonists from Glaxo Wellcome

Sep. 13, 1996

Another NeuroSearch compound for nerve degeneration

Sep. 6, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...